Cargando…

Apolipoprotein E Genotype e2: Neuroprotection and Its Limits

In this review, we comprehensively, qualitatively, and critically synthesized several features of APOE-e2, a known APOE protective variant, including its associations with longevity, cognition, and neuroimaging, and neuropathology, all in humans. If e2’s protective effects—and their limits—could be...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyun, Devanand, Davangere P., Carlson, Scott, Goldberg, Terry E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329577/
https://www.ncbi.nlm.nih.gov/pubmed/35912085
http://dx.doi.org/10.3389/fnagi.2022.919712
_version_ 1784757946606944256
author Kim, Hyun
Devanand, Davangere P.
Carlson, Scott
Goldberg, Terry E.
author_facet Kim, Hyun
Devanand, Davangere P.
Carlson, Scott
Goldberg, Terry E.
author_sort Kim, Hyun
collection PubMed
description In this review, we comprehensively, qualitatively, and critically synthesized several features of APOE-e2, a known APOE protective variant, including its associations with longevity, cognition, and neuroimaging, and neuropathology, all in humans. If e2’s protective effects—and their limits—could be elucidated, it could offer therapeutic windows for Alzheimer’s disease (AD) prevention or amelioration. Literature examining e2 within the years 1994–2021 were considered for this review. Studies on human subjects were selectively reviewed and were excluded if observation of e2 was not specified. Effects of e2 were compared with e3 and e4, separately and as a combined non-e2 group. Our examination of existing literature indicated that the most robust protective role of e2 is in longevity and AD neuropathologies, but e2’s effect on cognition and other AD imaging markers (brain structure, function, and metabolism) were inconsistent, thus inconclusive. Notably, e2 was associated with greater risk of non-AD proteinopathies and a disadvantageous cerebrovascular profile. We identified multiple methodological shortcomings of the literature on brain function and cognition that could have contributed to inconsistent and potentially misleading findings. We make careful interpretations of existing findings and provide directions for research strategies that could effectively examine the independent and unbiased effect of e2 on AD risk.
format Online
Article
Text
id pubmed-9329577
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93295772022-07-29 Apolipoprotein E Genotype e2: Neuroprotection and Its Limits Kim, Hyun Devanand, Davangere P. Carlson, Scott Goldberg, Terry E. Front Aging Neurosci Neuroscience In this review, we comprehensively, qualitatively, and critically synthesized several features of APOE-e2, a known APOE protective variant, including its associations with longevity, cognition, and neuroimaging, and neuropathology, all in humans. If e2’s protective effects—and their limits—could be elucidated, it could offer therapeutic windows for Alzheimer’s disease (AD) prevention or amelioration. Literature examining e2 within the years 1994–2021 were considered for this review. Studies on human subjects were selectively reviewed and were excluded if observation of e2 was not specified. Effects of e2 were compared with e3 and e4, separately and as a combined non-e2 group. Our examination of existing literature indicated that the most robust protective role of e2 is in longevity and AD neuropathologies, but e2’s effect on cognition and other AD imaging markers (brain structure, function, and metabolism) were inconsistent, thus inconclusive. Notably, e2 was associated with greater risk of non-AD proteinopathies and a disadvantageous cerebrovascular profile. We identified multiple methodological shortcomings of the literature on brain function and cognition that could have contributed to inconsistent and potentially misleading findings. We make careful interpretations of existing findings and provide directions for research strategies that could effectively examine the independent and unbiased effect of e2 on AD risk. Frontiers Media S.A. 2022-07-14 /pmc/articles/PMC9329577/ /pubmed/35912085 http://dx.doi.org/10.3389/fnagi.2022.919712 Text en Copyright © 2022 Kim, Devanand, Carlson and Goldberg. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Kim, Hyun
Devanand, Davangere P.
Carlson, Scott
Goldberg, Terry E.
Apolipoprotein E Genotype e2: Neuroprotection and Its Limits
title Apolipoprotein E Genotype e2: Neuroprotection and Its Limits
title_full Apolipoprotein E Genotype e2: Neuroprotection and Its Limits
title_fullStr Apolipoprotein E Genotype e2: Neuroprotection and Its Limits
title_full_unstemmed Apolipoprotein E Genotype e2: Neuroprotection and Its Limits
title_short Apolipoprotein E Genotype e2: Neuroprotection and Its Limits
title_sort apolipoprotein e genotype e2: neuroprotection and its limits
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329577/
https://www.ncbi.nlm.nih.gov/pubmed/35912085
http://dx.doi.org/10.3389/fnagi.2022.919712
work_keys_str_mv AT kimhyun apolipoproteinegenotypee2neuroprotectionanditslimits
AT devananddavangerep apolipoproteinegenotypee2neuroprotectionanditslimits
AT carlsonscott apolipoproteinegenotypee2neuroprotectionanditslimits
AT goldbergterrye apolipoproteinegenotypee2neuroprotectionanditslimits